Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Escherichia coli in female adolescents

References

• Bonny AE, Brouhard BH. Urinary tract infections among adolescents. Adolesc Med Clin. 2005;16(1):149–161.
   PubMedGoogle Scholar
• Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–e120.
   PubMed Web of Science ®Google Scholar
• Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis. 2016;63(7):960–965.
   PubMed Web of Science ®Google Scholar
• Bryce A, Hay AD, Lane IF, et al. Global prevalence of antibiotic resistance in pediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ. 2016;352:i939.
   PubMed Web of Science ®Google Scholar
• Mahony M, McMullan B, Brown J, et al. Multidrug-resistant organisms in urinary tract infections in children. Pediatr Nephrol. 2020;35(9):1563–1573.
   PubMed Web of Science ®Google Scholar
• Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53(4):637–656.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Legakis NJ, Triarides N, et al. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016;47(4):269–285.
   PubMed Web of Science ®Google Scholar
• Monurol (fosfomycin tromethamine) oral suspension – FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050717s007lbl.pdf. 2011.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_Breakpoint_Tables.pdf. 2017.
   Google Scholar
• World Health Organization. Critically important antimicrobials for human medicine, 6th revision. Geneva. https://apps.who.int/iris/bitstream/handle/10665/312266/9789241515528-eng.pdf. 2019.
   Google Scholar
• Monuril 3g granules for oral solution. Summary of product characteristics, UK. Zambon S.p.A. https://www.medicines.org.uk/emc/product/7329/smpc#grefJ. 2020.
   Google Scholar
• Australian Public Assessment Report for Fosfomycin Trometamol. https://www.tga.gov.au/sites/default/files/auspar-fosfomycin-trometamol-180907.pdf. 2018.
   Google Scholar
• Principi N, Corda R, Bassetti D, et al. Fosfomycin trometamol versus netilmicin in children’s lower urinary tract infections. Chemotherapy. 1990;36(1):41–45.
   PubMedGoogle Scholar
• Varese LA. Trometamol salt of fosfomycin versus netilmicin: randomized multicenter study in children’s lower urinary tract infections. Eur Urol. 1987;13(1):119–121.
   PubMedGoogle Scholar
• Careddu P, Borzani M, Scotti L, et al. Treatment of lower urinary tract infections in children: single dose fosfomycin trometamol versus pipemidic acid. Chemioterapia. 1987;6(4):290–294.
   PubMedGoogle Scholar
• Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(9):1862–1877.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Zhanel MA, Karlowsky JA. Oral and intravenous fosfomycin for the treatment of complicated urinary tract infections. Can J Infect Dis Med Microbiol. 2020;2020:8513405.
   PubMed Web of Science ®Google Scholar
• Seroy JT, Grim SA, Reid GE, et al. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. J Antimicrob Chemother. 2016;71(9):2563–2568.
   PubMed Web of Science ®Google Scholar
• Wenzler E, Bleasdale SC, Sikka M, et al. Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants. Antimicrob Agents Chemother. 2018;62(8):e00464–18.
   PubMed Web of Science ®Google Scholar
• Babiker A, Clarke L, Doi Y, et al. Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature. Diagn Microbiol Infect Dis. 2019;95(3):114856.
   PubMed Web of Science ®Google Scholar
• Pullukcu H, Tasbakan M, Sipahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections . Int J Antimicrob Agents. 2007;29(1):62–65.
   PubMed Web of Science ®Google Scholar
• Neuner EA, Sekeres J, Hall GS, et al. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother. 2012;56(11):5744–5748.
   PubMed Web of Science ®Google Scholar
• Veve MP, Wagner JL, Kenney RM, et al. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents. 2016;48(1):56–60.
   PubMed Web of Science ®Google Scholar
• Giancola SE, Mahoney MV, Hogan MD, et al. Assessment of fosfomycin for complicated or multidrug-resistant urinary tract infections: Patient characteristics and outcomes. Chemotherapy. 2017;62(2):100–104.
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Raux BR, Zucchi PC, Kim Y, et al. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates. Int J Antimicrob Agents. 2015;46(6):642–647.
   PubMed Web of Science ®Google Scholar
• Matthews PC, Barrett LK, Warren S, et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis. 2016;16(1):556.
   PubMed Web of Science ®Google Scholar
• Azzarone G, Liewehr S, O'Connor K. Cystitis. Pediatr Rev. 2007;28(12):474–476.
   PubMedGoogle Scholar